BioSpace News Archive

Lumenis announced the completion of the sale of its Surgical business to Boston Scientific Corporation, a leading global medical device manufacturer, in a transaction valued at $1.07B.

Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive, will participate in a virtual fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.

Lumen Bioscience today announced the start of a Phase 1 trial of LMN-Cdiff01, an orally delivered investigational biologic for treatment and prevention of recurrent C. difficile infection (CDI).

Exicure , Inc. today announced participation in the following investor conferences during the month of September: Citi’s 16th Annual Biopharma Conference 2021 One-on-one meetings September 8-10, 2021

AVROBIO, Inc. today announced that members of its senior management team are scheduled to participate in four upcoming virtual investor conferences.

Fractyl Health, a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, today announced the activation of the tenth clinical site in the company’s pivotal REVITA-T2Di trial taking place across the U.S. and Europe.

Spire Global, Inc announced today that it is attending the RBC Capital Markets Global Industrials Virtual Conference and that CEO Peter Platzer, will participate in a fireside chat to be held virtually on Friday, September 10 at 10:00 AM ET.

Fact.MR – A Market Research and Competitive Intelligence Provider: The global capnography market is set to witness steady growth between 2021 and 2031.

Photocure ASA, the Bladder Cancer Company, announced the appointment of Anders Neijber as Vice President, Global Medical Affairs and Clinical Development, effective September 1st, 2021.

MedinCell and Teva announced yesterday the FDA acceptance of the New Drug Application for mdc-IRM for patients with schizophrenia.